NEW YORK ( TheStreet) -- Ardea Biosciences (Nasdaq: RDEA) hit a new 52-week low Monday as it is currently trading at $16.95, below its previous 52-week low of $18.11 with 14,531 shares traded as of 9:54 a.m. ET. Average volume has been 127,000 shares over the past 30 days.

Ardea has a market cap of $536 million and is part of the health care sector and drugs industry. Shares are down 29.9% year to date as of the close of trading on Friday.

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States.
  • Practice your RDEA trading strategies and win cash in our stock game.

TheStreet Ratings rates Ardea as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. You can view the full Ardea Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.